No products in the cart
Vilon peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
Out of stock
What is the Vilon peptide?
Vilon (or Lyslglutamic Acid) is a peptide with apparent immunomodulatory and anti-aging bioregulation features. It is a short peptide with just two amino acids in length, suggested to have strong biological functions. Scientific research suggests it is also a potent regulator of the vascular system and better hemostasis. Its functions may be more widespread, with studies indicating its potential to reduce in the prevalence and growth of spontaneous tumors, though its role as an ancillary is under review. Advocates like Dr. Vladimir Anisimov believe that the peptide could be vital in geroprotection (anti-aging) as a potential geroprotective agent.
Sequence Formula: H-Lys-Glu-OH
Molecular Formula: C11N21N3O5
Molecular Weight: 257.30g/mol
PubChem: CID 7010502
Synonyms: Lysylglutamate, normophthal, Lyslglutamic acid
Vilon and Cancer
Vilon, according to research, may reduce the prevalence of cancer in mouse models, which in turn will impact longevity. Studies report that administration of the peptide may reduce tumor prevalence and stop growth, suggesting that Vilon may be a potent chemotherapeutic agent and an add-on to the arsenal of existing cancer treatments. Vilon may therefore exhibit benefits ranging in chemotherapy to treatment with radiation and surgery. Scientific studies reported negative results when Vilon was combined with a platinum-based chemotherapeutic agent, and in chemotherapy following cancer. The anti-cancer potential of Vilon and its usefulness as an adjuvant in chemotherapy is still under investigation and studies are not yet conclusive. The scientists also revealed that “Vilon stimulated apoptosis both in young and old rats, but the inhibitory effect of cyclophosphan was abolished in the presence of vilon in culture media”
Vilon and the Immune System
Studies in Vilon expression suggest that it may be a potent chromatin structure regulator. Studies reported that Vilon administration may lead to potential:
1. activation of chromatin unrolling
2. release of repressed genes
3. activation of synthetic processes through the reactivation of ribosomal genes in the unrolled chromatin
4. and it does not appear to cause structural chromatin decondensation
The research that lead to the development of these hypotheses further suggest that Vilon may induce the reactivation of silenced DNA genes. Generally, Chromatin presents as heterochromatin and euchromatin. Genes in the heterochromatin aspect of DNA are inaccessible to the production of proteins. The condensation of Chromatin occurs due to aging and senescence, and points to why our cells and tissues lose functionality as a person advances in age. The possible ability of Vilon in symbiosis with other peptide bioregulators to reactivate specific genes unrolling heterochromatin may improve immune function in older adults. The researchers reported that “peptide bioregulators Epitalon, Livagen and Vilon cause activation (deheterochromatinization) of chromatin in lymphocytes of old individuals.” Furthermore, Interleukin-2 may be vital in immune response coordination to microbial infection, as it helps inhibit the prevalence of autoimmune reactions. The activation of interleukin-2 signaling is one suggested action of Vilon peptide in the spleen. Vilon may reinstate the immune system to a more effective state and may be handy in ushering in treatments for autoimmune diseases by activating lymphocytes and splenocytes—boosting natural prevention against the prevalence of autoimmune reactions. Vilon, according to research, may enhance the propagation of CD5 T-cells in the thymus. CD5 is a potent immunohistochemical marker for T-helper cells and cytotoxic CD8 T-cells. The action of Vilon could help to influence the immune system and prevent the prevalence of autoimmune reactions. Vilon appears to function only to reactivate the immune system functions through genes that have been silenced via chromatin changes. It doesn’t appear to actuate genes that would be silent in the cells it modifies.
Vilon and the Kidneys, Heart
Vilon’s effect on vasculature hasn’t been well studied, but some scientific studies suggest that it may be beneficial. Research in mice posits that Vilon alters more than 36 gene expressions in the heart. When in combination with Epithalon, this number was reported to elevate to 144 genes. These results indicate that Vilon may influence gene expression trend in the cardiovascular system, which may improve hemodynamic function. Research suggests that Vilon may reduce concentrations of TGF-beta 1 in the kidneys and highly vascular organs, allowing for permeability of microvessels. The final result is better hemostasis during kidney failure, positing that Vilon may be beneficial in the vascular system. Research in older patients with diabetes reports that Vilon (Lyslglutamic Acid) may bolster coagulation by enhancing the antithrombin III anticoagulant levels and Protein C, even as it stimulates fibrinolysis. The consequence of this is lesser blood clots in clotting-prone populations.
Vilon and Aging
Administration of the Vilon peptide appears to enhance physical performance and endurance even as it decreases the prevalence of cancer cells. In mouse models, these two apparent functions of the peptide amounted to extended longevity, with no adverse side effects sequel to long-term administration. According to research, the administration of Vilon in early life may increase longevity. The hypothesis holds that the administration of Vilon in late life may reverse senescence in existing cells but cannot do the same for cells that have been discarded via apoptosis. In the same sense, the administration of Vilon in early life may increase a degree of protection, and modification is lowered. Consequently, many cells may stay healthy for extended periods, reducing the need to change them and retaining limited stem cell lines. Vilon’s apparent anti-aging effect isn’t limited—extending to GI functions, where it appears to better the enzyme activity in the GI tracts of aged mice. It also may improve the barrier function—reducing the prevalence of leaky gut, increasing resistance to diseases, and bettering the health of the GI tract in aged mice. Vilon may help keep nutrient extraction in check by enhancing glucose and glycine absorption, which will result in overall health and extended longevity. According to research by Dr. Vladimir N. Anisimov, two glands, the thymus and pineas, are vital regulators of aging. A healthy individual will typically have a healthy thymus. It is important to note that Vilon is a thymic peptide and appears to act on lymphocytes and other cells produced in the thymus. Vilon (Lyslglutamic Acid) is limited to educational and scientific studies only, and is not for human consumption.
- Khavinson VKh, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000 May-Jun;372:261-3. PMID: 10944717.
- Barykina OP, Iuzhakov VV, Chalisova NI, Kvetnoĭ IM, Konovalov SS. Sochetannoe vliianie vilona i tsiklofosfana na transplanty opukholeĭ i éksplantaty limfoidnoĭ tkani mysheĭ i krys raznogo vozrasta [Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]. Adv Gerontol. 2003;12:128-31. Russian. PMID: 14743610.
- Lezhava T, Khavison V, Monaselidze J, Jokhadze T, Dvalishvili N, Bablishvili N, Barbakadze S. Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. Biogerontology. 2004;5(2):73-9. doi: 10.1023/B:BGEN.0000025070.90330.7f. PMID: 15105581.
- Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Med News. 2006 Apr;(133):111-5. PMID: 16705247.
- Gavrisheva NA, Malinin VV, Ses TP, Kozlov KL, Panchenko AV, Titkov AY. Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure. Bull Exp Biol Med. 2005 Jan;139(1):24-6. doi: 10.1007/s10517-005-0202-9. PMID: 16142267.
- Kuznik BI, Isakova NV, Kliuchereva NN, Maleeva NV, Pinelis IS. [Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus]. Adv Gerontol. 2007;20(2):106-15. Russian. PMID: 18306698
- Anisimov VN, Loktionov AS, Khavinson VK, Morozov VG. Effect of low-molecular-weight factors of thymus and pineal gland on life span and spontaneous tumour development in female mice of different age. Mech Ageing Dev. 1989 Sep;49(3):245-57. doi: 10.1016/0047-6374(89)90075-4. PMID: 2682058.
- Anisimov VN, Khavinson VKh. [The use of peptide bioregulators for cancer prevention: results of 35 years of research experience and perspectives]. Vopr Onkol. 2009;55(3):291-304. Russian. PMID: 19670728.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.
There are no reviews yet.